Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next
Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that it will acquire European telehealth platform Zava. The acquisition gro [...]
Hims & Hers stock tumbles as the FDA issues a warning about 'unapproved' weight loss drugs
Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company braces for big regulatory shifts in the weight-loss drug industry.Read more. [...]
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]
Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy, the company [...]
Wegovy sales took a hit this year. Novo's CEO blames off-brand competition
Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or compounded, versions of the treatment, according to the Danish pharma giantâ [...]
Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patients
Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half for even more patients that pay without insurance.Read more... [...]